A phase Ib trial in patients with mild Alzheimer’s disease demonstrated a greater than 50% reduction in CSF tau levels (22), and a phase II trial is ongoing (NCT05399888). Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.